Pharmaceutical company in
Epalinges
32 companies in Pharmaceutical company based in Epalinges — name and year of registration from the commercial register. The list below shows them all.
All 32 companies in Epalinges
PRECLIN Biosystems SA
Since 2008 · 1–10 empl.
PRECLIN Biosystems SA provides a comprehensive in vivo preclinical testing platform for the identification and validation of lead therapeutic candidates and specializes in preclinical models of chronic inflammatory and infectious diseases.
NovaPharm SA
Since 2008 · 1–10 empl.
NovaPharm SA provides consulting, services and trading in the healthcare sector, including market access, distribution, sourcing and regulatory compliance. The company conducts purchase and resale of medicines and health products and holds a Swissmedic authorization for trading.
Combioxin SA
Since 2015 · 11–20 empl.
The core activity of Combioxin SA is the development of life-saving medications for severe infections, particularly for the treatment of severe bacterial pneumonias. The company focuses on the development of innovative therapeutics, such as CAL02, a first-in-class anti-toxin agent used to neutralize virulence factors that play a crucial role in the development of organ failure and fatal complications in severe infections.
LAM Biotechnologies SA
Since 2018 · 1–10 empl.
LAM Biotechnologies SA is a biotechnology company focused on research and development, production of its own products, and sales and marketing of those products. It also provides services in diagnostics, platform technologies, analytical testing, screening, and bioinformatics.
Haya Therapeutics SA
Since 2019 · 21–50 empl.
The company develops precise therapeutics based on genome research and biotechnology. It focuses on the development of medicines and therapies, particularly in the field of cardiovascular diseases and regenerative medicine. The core activity includes research and development of new medicines, identification and evaluation of new business opportunities, conducting due diligence reviews, and managing portfolio companies.
Onward Therapeutics SA
Since 2019 · 1–10 empl.
The core activity of Onward Therapeutics is the development of innovative cancer treatments, particularly through the identification and development of potential active substances and technologies in the field of immunotherapy and oncology. The company focuses on the development of drugs that support the immune system to fight cancer, and works with partners to develop and market transformative technologies.
Vandria SA
Since 2021 · 21–50 empl.
Vandria SA is a clinical-stage biotech company developing first-in-class small molecules against a novel metabolic target to restore mitochondrial function and reduce chronic inflammation for the treatment of age-related and chronic diseases. Its lead clinical CNS asset, VNA-318, is an orally available, brain-penetrant small molecule that completed Phase I studies demonstrating safety, tolerability and a pharmacokinetic profile suitable for once-daily oral dosing.
Dorphan SA
Since 2011 · 1–10 empl.
PDC Therapeutics SA
Since 2020 · 1–10 empl.
PDC Therapeutics SA is a biotechnology company developing targeted nanomedicines based on polymer-drug conjugates. Its pipeline includes targeted chemotherapy programs as well as radioligand diagnostics and therapies.
ADC Therapeutics SA
Since 2011 · 11–20 empl.5.0(1)
ADC Therapeutics SA is a biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer treatment. Its portfolio includes ZYNLONTA® and clinical studies evaluating its use in different types of lymphoma.
Exogems SA
Since 2022 · 1–10 empl.
Exogems SA is a Swiss biotech company developing exosome-based therapeutics for inflammation and regenerative medicine. The company works with the Lipogems® platform and proprietary technology to isolate and produce clinical-grade exosomes from adipose tissue.
DigeHealth SA
Since 2023 · 1–10 empl.
DigeHealth SA develops wearable devices and software for continuous gut monitoring by recording bowel sounds and physiological metrics such as heart rate and activity. The company combines these data with AI-powered bowel sound recognition to provide real-world data for researchers and users; its products are not medical devices and are intended for research and personal use.
Legacy Healthcare (Switzerland) SA
Since 2007 · 21–50 empl.1.0(1)
Legacy Healthcare (Switzerland) SA is a biopharmaceutical company that develops prescription botanical drugs for autoimmune and inflammatory conditions. Its lead product candidate, CINAINU, is a topical botanical formulation that showed superiority to placebo in a phase 2/3 study (RAAINBOW) in moderate and severe alopecia areata and is being advanced through clinical and regulatory programs.
Gnubiotics Sciences SA
Since 2016 · 1–10 empl.5.0(1)
The core activity of Gnubiotics is the development of innovative therapeutics for the treatment of cancer, particularly Immuno-Oncology (I/O) resistant cancer types, through the application of the so-called "Tumor Glycocode" technology. This technology aims to break the tumor glycocode, thereby activating the body's own immune response to combat tumor cells. In this context, the company develops specific glycopeptide formulations, such as GNU101, which promote cytotoxic T-cell activity in the tumor and can be used as biomarkers in diseases such as colorectal cancer.
Signal26 Biotherapeutics SA
Since 2024 · 1–10 empl.
Signal26 Biotherapeutics SA is a biotechnology company developing a monoclonal antibody against interleukin 26 (IL-26) as a biologic treatment for pustular psoriasis. It also researches the role of IL-26 in autoimmune and inflammatory diseases, including inflammatory bowel disease and rheumatoid arthritis.
Opna Bio Switzerland Sàrl
Since 2025 · 1–10 empl.
Opna Bio Switzerland Sàrl is a clinical-stage biopharmaceutical company focused on discovering and developing novel cancer therapeutics. Its pipeline includes programs for multiple myeloma, myelofibrosis and other oncology targets.
ND BioSciences SA
Since 2019 · 1–10 empl.5.0(1)
ND BioSciences SA develops next-generation therapeutics and diagnostic assays for neurodegenerative diseases using validated and patented protein‑engineering and cellular drug‑discovery platforms. The company, a spin-off from the École polytechnique fédérale de Lausanne (EPFL), applies models that reproduce pathogenic protein aggregates and aggregation stages to support drug and biomarker development.
ANABIOTEC, à Evergem, succursale de Epalinges (VD)
Since 2025 · 1–10 empl.
ANABIOTEC, à Evergem, succursale de Epalinges (VD) provides analytical services for drug development, with a focus on CMC analytics and (pre-)clinical bioanalysis. The company supports method development, method validation, stability studies, characterization studies, and release testing for synthetic, biological, and cell and gene therapy products.
Synameta Therapeutics SARL
Since 2025 · 1–10 empl.
Synameta Therapeutics SARL develops an exosome-based platform for targeted therapeutic delivery. The company works on virus-free biovectors for applications in oncology and gene therapy.
Exciva Switzerland SA
Since 2026 · 1–10 empl.
Exciva Switzerland SA develops clinical-stage therapeutics for neuropsychiatric symptoms in Alzheimer’s disease dementia, with a focus on agitation. The company advances a lead drug program and conducts clinical studies related to Alzheimer’s disease.
Swiss Biotech Laboratories Europe Sàrl
Since 2026 · 1–10 empl.
Swiss Biotech Laboratories Europe Sàrl is a research and production unit active in biotechnology, analytical chemistry, and molecular biology. The company provides laboratory research, analytical services, contract research, and small-scale specialized production for clients in pharma, cosmetics, and biomedicine.
NATULYS Sàrl
Since 2006 · 1–10 empl.
NATULYS Sàrl is a laboratory focused on phytotherapy that produces natural products for joint, muscle, bone and tendon health. Offerings include Silorga (a liquid organic silicon solution), Silconfort (a silicon gel) and supplements containing glucosamine, chondroitin sulfate, harpagophytum and turmeric, distributed in Switzerland and Europe via distributors and online.
Griffon Pharmaceuticals International SA
Since 2019 · 1–10 empl.
RadioMedix Europe Sàrl
Since 2019 · 1–10 empl.
NUVAMID SA
Since 2019 · 1–10 empl.
Onkion SA
Since 2020 · 1–10 empl.
Cellula Therapeutics SA
Since 2023 · 1–10 empl.
PalmeaPharma SA
Since 2023 · 1–10 empl.
IGI Therapeutics SA, succursale d'Epalinges
Since 2025 · 1–10 empl.
VivoXpand Sàrl
Since 2025 · 1–10 empl.
Tubulis Sàrl
Since 2025 · 1–10 empl.
EpiKare Bio SA
Since 2025 · 1–10 empl.
Pharmaceutical company in Epalinges
Pharmaceutical company in other places
By canton